Navigation Links
WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training

SHANGHAI, March 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. (JANSSEN), to collaborate in the area of preclinical services.

(Logo: )

Under the agreement, WuXi PharmaTech will become a provider of toxicology and other non-clinical services to JANSSEN. In addition, JANSSEN will provide training and other services, reimbursed by WuXi, to establish the GLP quality system and technical capabilities to meet the international standards at WuXi's toxicology facility in Suzhou, China.

Construction of this facility, the largest in China with 314,000 square feet of space, was completed at the end of 2008. In 2009, the company hired a management team with extensive international experience and made substantial progress in training an initial staff of technicians to perform GLP services. The facility is currently conducting non-GLP toxicology services, as well as client-sponsored GLP validation studies to demonstrate our growing capabilities. The company remains on target to begin offering GLP toxicology studies by mid-2010.

Commenting on the agreement, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, said, "We are pleased to establish this new partnership with JANSSEN, which builds on our existing agreement to provide them with integrated pharmaceutical R&D services. We believe that China, with its high-quality scientific talent and favorable cost structure, is destined to become a major center for toxicology services over the next decade. We aim to become a leading provider of these services and to add toxicology to WuXi's broad, integrated platform of laboratory and preclinical services."

    For more information, please contact:

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362

SOURCE WuXi PharmaTech (Cayman) Inc.

Back to top
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
2. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
3. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
8. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
9. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
Post Your Comments:
(Date:10/13/2015)... 13, 2015 TriGuard™ Cerebral Protection ... findings from the multicenter Neuro-TAVR study with the clinical ... San Francisco this week. --> ... will be sharing additional findings from the multicenter Neuro-TAVR ... (TCT) meeting in San Francisco ...
(Date:10/13/2015)... According to the 2015 National ... Cardinal Health , achieving both higher patient ... revenue streams are vital to the future success ... Digest affirms that independent community pharmacies are ... inner city and rural areas," said NCPA CEO ...
(Date:10/13/2015)... WASHINGTON , Oct. 13, 2015  Measurement ... quality improvement and balancing financial incentives, but gaps ... improve patient care and health systems. A new, ... Journal of Managed Care explores measurement ... improve measure sets. --> ...
Breaking Medicine Technology:
(Date:10/13/2015)... Pennsylvania (PRWEB) , ... October 13, 2015 , ... ... people through a unique private messaging application, announced today a significant contract that ... another five years. Independence plans to build on the growing success of its ...
(Date:10/13/2015)... , ... October 13, 2015 , ... A child without ... why SmileCareClub , the leading remote invisible aligner system, has joined with ... otherwise go without it. For each aligner treatment plan purchased, SmileCareClub will donate one ...
(Date:10/13/2015)... , ... October 13, 2015 ... ... Omega-3, a first-of-its kind product that targets the unique health needs of ... of the American Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, ...
(Date:10/13/2015)... ... ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, pain free ... more than 5 years. A leading cause of emergency room visits, school absences, and ... timely. , Sedation dentistry provides an anxiety-free dental experience with safe ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an ... an orbital fracture when a teammate accidentally elbowed him in the left eye during ... eye injury is just one of a series of setbacks, including a knee injury ...
Breaking Medicine News(10 mins):